MétaCan
Menu
Back to cohort
Record W2102925061 · doi:10.1158/1078-0432.ccr-10-3405

The Role of <i>KRAS</i> rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing

2011· article· en· W2102925061 on OpenAlexaff
Paul D.P. Pharoah, Rachel T. Palmieri, Susan J. Ramus, Simon A. Gayther, Irene L. Andrulis, Hoda Anton‐Culver, Natalia Antonenkova, Antonis C. Antoniou, David E. Goldgar, Mary Beattie, Matthias W. Beckmann, Michael J. Birrer, Natalia Bogdanova, Kelly L. Bolton, Wendy R. Brewster, Angela Brooks‐Wilson, Robert Brown, Ralf Bützow, Trinidad Caldés, Maria A. Caligo, Ian Campbell, Jenny Chang‐Claude, Y. Ann Chen, Linda S. Cook, Fergus J. Couch, Daniel W. Cramer, Julie M. Cunningham, Evelyn Despierre, Jennifer A. Doherty, Thilo Dörk, Matthias Dürst, Arif B. Ekici, Douglas F. Easton, Peter A. Fasching, Anna de Fazio, David Fenstermacher, James M. Flanagan, Brooke L. Fridley, Eitan Friedman, Bo Gao, Olga M. Sinilnikova, Aleksandra Gentry‐Maharaj, Andrew K. Godwin, Ellen L. Goode, Marc T. Goodman, Jenny Gross, Thomas van Overeem Hansen, Paul R. Harnett, Matti A. Rookus, Tuomas Heikkinen, Rebecca Hein, Claus Høgdall, Estrid Høgdall, Edwin S. Iversen, Anna Jakubowska, Sharon E. Johnatty, Beth Y. Karlan, Noah D. Kauff, Stanley B. Kaye, Georgia Chenevix‐Trench, Linda E. Kelemen, Lambertus A. Kiemeney, Susanne K. Kjær, Diether Lambrechts, James P. LaPolla, Conxi Lázaro, Nhu D. Le, Arto Leminen, Karin Leunen, Douglas A. Levine, Yi Lu, Lene Lundvall, Stuart MacGregor, Tamara Marees, Leon F.A.G. Massuger, Usha Menon, Marco Montagna, Kirsten B. Moysich, Steven A. Narod, Katherine L. Nathanson, Lotte Nedergaard, Roberta B. Ness, Heli Nevanlinna, Stefan Nickels, Ana Osório, Celeste Leigh Pearce, Catherine M. Phelan, Malcolm C. Pike, Paolo Radice, Mary Anne Rossing, Joellen M. Schildkraut, Thomas A. Sellers, Christian F. Singer, Honglin Song, Daniel O. Stram, Rebecca Sutphen, Annika Lindblom, Kathryn L. Terry, Ya-Yu Tsai, Anne M. van Altena, Ignace Vergote, Robert A. Vierkant, Allison F. Vitonis, Christine Walsh, Shan Wang‐Gohrke, Barbara Wappenschmidt, Anna H. Wu, Argyrios Ziogas, Andrew Berchuck, Harvey A. Risch

Bibliographic record

VenueClinical Cancer Research · 2011
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsCancer Care Ontario
FundersNational Cancer InstituteCancer Research UKPeter MacCallum Cancer CentreWellcome TrustFriedrich-Schiller-Universität JenaMoffitt Cancer CenterUniversity of South FloridaDeutsches KrebsforschungszentrumHelsingin ja Uudenmaan SairaanhoitopiiriUniversity College LondonHelsingin Yliopisto
KeywordsKRASOvarian cancerEpithelial ovarian cancerMedicineCancerOncologyInternal medicinePathologyGynecologyCancer researchBiologyColorectal cancer

Abstract

fetched live from OpenAlex

PURPOSE: An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published article, analyzing fewer than 1,000 subjects in total, has examined this association. EXPERIMENTAL DESIGN: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from 19 studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in a subset of five studies with progression-free survival (PFS) data and 18 studies with all-cause mortality data. RESULTS: No evidence of association was observed between genotype and risk of unselected EOC (OR = 1.02, 95% CI: 0.95-1.10), serous EOC (OR = 1.08, 95% CI: 0.98-1.18), familial EOC (OR = 1.09, 95% CI: 0.78-1.54), or among women carrying deleterious mutations in BRCA1 (OR = 1.09, 95% CI: 0.88-1.36). There was little evidence for association with survival time among unselected cases (HR = 1.10, 95% CI: 0.99-1.22), among serous cases (HR = 1.12, 95% CI = 0.99-1.28), or with PFS in 540 cases treated with carboplatin and paclitaxel (HR = 1.18, 95% CI: 0.93-1.52). CONCLUSIONS: These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for ovarian cancer clinical risk prediction, therefore, seems unwarranted.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.015
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.036

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.015
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.534
GPT teacher head0.568
Teacher spread0.035 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations47
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicOvarian cancer diagnosis and treatmentFrench-language works237,207